
OptiNose OPTN
Quartalsbericht 2025-Q1
hinzugefügt 14.05.2025
OptiNose EV 2011-2026 | OPTN
EV Jährlich OptiNose
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 312 M | 264 M | 169 M | 230 M | 309 M | 140 M | 68.6 M | 8.59 M | 43.2 M | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 312 M | 8.59 M | 172 M |
EV anderer Aktien in der Arzneimittelhersteller
| Name | EV | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Endo International plc
ENDP
|
-710 M | - | - | $ 28.9 M | ||
|
Evoke Pharma
EVOK
|
-3.12 M | - | - | $ 36.6 M | ||
|
HEXO Corp.
HEXO
|
560 M | - | 2.45 % | $ 38.1 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
-974 M | - | -0.1 % | $ 2.03 B | ||
|
AcelRx Pharmaceuticals
ACRX
|
6.79 M | - | 7.5 % | $ 6.35 M | ||
|
DURECT Corporation
DRRX
|
-11 M | - | - | $ 50.1 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
28.5 M | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
737 M | - | - | $ 754 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
126 M | $ 6.17 | 3.14 % | $ 91.7 M | ||
|
Agile Therapeutics
AGRX
|
25.3 M | - | 10.11 % | $ 58.2 M | ||
|
Alimera Sciences
ALIM
|
197 M | - | - | $ 142 M | ||
|
Cronos Group
CRON
|
-1.35 M | $ 2.84 | -0.04 % | $ 1.09 B | ||
|
Athenex
ATNX
|
209 M | - | -23.39 % | $ 1.76 M | ||
|
Harrow Health
HROW
|
2.21 B | $ 34.76 | -1.79 % | $ 1.28 B | ||
|
Avadel Pharmaceuticals plc
AVDL
|
756 M | - | - | $ 2.06 B | ||
|
Catalent
CTLT
|
16.7 B | - | - | $ 11.5 B | ||
|
Eagle Pharmaceuticals
EGRX
|
457 M | - | -39.89 % | $ 27.7 M | ||
|
Pacira BioSciences
PCRX
|
1.68 B | $ 23.54 | -0.61 % | $ 1.09 B | ||
|
Bausch Health Companies
BHC
|
26.7 B | $ 5.31 | -1.94 % | $ 1.97 B | ||
|
Organogenesis Holdings
ORGO
|
408 M | $ 2.56 | -2.48 % | $ 324 M | ||
|
Canopy Growth Corporation
CGC
|
459 M | $ 1.09 | -2.54 % | $ 117 M | ||
|
Solid Biosciences
SLDB
|
616 M | $ 7.32 | 3.54 % | $ 641 M | ||
|
Aurora Cannabis
ACB
|
330 M | $ 3.65 | -0.55 % | $ 200 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
7.57 M | $ 1.15 | 3.6 % | $ 1.43 M | ||
|
Jupiter Wellness
JUPW
|
3.7 M | - | - | $ 33.6 M | ||
|
Tilray
TLRY
|
1.96 B | $ 5.58 | -1.33 % | $ 3.45 B | ||
|
Lannett Company
LCI
|
648 M | - | 1.15 % | $ 7.11 M | ||
|
OrganiGram Holdings
OGI
|
146 M | $ 1.16 | 1.63 % | $ 111 M | ||
|
Evolus
EOLS
|
467 M | $ 6.61 | 0.61 % | $ 426 M | ||
|
Sundial Growers
SNDL
|
-17.5 M | $ 1.49 | -0.34 % | $ 3.37 M | ||
|
Emergent BioSolutions
EBS
|
1.04 B | $ 9.32 | 1.47 % | $ 499 M | ||
|
Veru
VERU
|
80.7 M | $ 2.33 | 0.43 % | $ 34.1 M | ||
|
Neoleukin Therapeutics
NLTX
|
-80.1 M | - | - | $ 193 M | ||
|
cbdMD
YCBD
|
4.51 M | $ 0.81 | -0.02 % | $ 3.26 M | ||
|
Assertio Holdings
ASRT
|
238 M | $ 23.44 | -0.02 % | $ 150 M | ||
|
ProPhase Labs
PRPH
|
145 M | - | - | $ 5.07 M | ||
|
Radius Health
RDUS
|
715 M | - | - | $ 1.42 B | ||
|
PetIQ
PETQ
|
280 M | - | 1.64 % | $ 400 M | ||
|
Relmada Therapeutics
RLMD
|
251 M | $ 7.16 | -1.24 % | $ 283 M | ||
|
Recro Pharma
REPH
|
220 M | - | -4.76 % | $ 65.3 M | ||
|
SCYNEXIS
SCYX
|
26.3 M | $ 0.73 | -0.72 % | $ 36.5 M | ||
|
PLx Pharma
PLXP
|
75 M | - | -27.8 % | $ 2.56 M | ||
|
Viatris
VTRS
|
21.2 B | $ 16.19 | 0.48 % | $ 18.8 B | ||
|
Zomedica Corp.
ZOM
|
2.62 M | - | -0.21 % | $ 98 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
-22.6 M | - | - | $ 55.5 M | ||
|
Rockwell Medical
RMTI
|
43.3 M | $ 0.75 | -1.47 % | $ 27 M | ||
|
Tricida
TCDA
|
555 M | - | - | $ 3.25 M | ||
|
China Pharma Holdings
CPHI
|
10.7 M | $ 0.81 | 4.41 % | $ 3.48 M | ||
|
TherapeuticsMD
TXMD
|
26.3 M | $ 2.08 | -1.66 % | $ 24.1 M |